Array Biopharma Inc.

Genentech, Inc.

Allen A Thomas

James F Blake

Steven Armen Boyd

Julia Haas

Gabrielle R Kolakowski

Huifen Chen

Li Ren

John Joseph Gaudino

Jacob Bradley Schwarz

Barbara J Brandhuber

Allison L Marlow

Peter J Mohr

Brad Newhouse

Indrani W Gunawardana

Shannon L Winski

Steven Wade Andrews

Yutong Jiang

Shelley Allen

Adam Wade Cook

Tony P Tang

David A Moreno

Lewis J Gazzard

Timothy S Kercher

Jeongbeob Seo

Andrew T Metcalf

Kevin W Hunt

Michael Lyon

Hongqi Tian

Jason De Meese

Jane Schmidt

Eli M Wallace

Mark Joseph Chicarelli

Kevin Ronald Condroski

Wendy B Young

Frederick Cohen

Kin Chiu Fong

Yvan Le Huerou

Rustam Ferdinand Garrey

Todd T Romoff

Steven Mark Wenglowsky

Robert J Kaus

Christopher Stephen Siedem

Jason Demeese

Francis X Sullivan

Stephen S Gonzales

Tomas Kaplan

Christopher S Siedem

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome. 

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Serine/threonine kinase inhibitors

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome. 

N-(arylalkyl)-N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors

Compounds having the formula I wherein Z, ZZZ, R, Rand Rand as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. 

Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Heterobicyclic thiophene compounds and methods of use

The present invention provides thioalkeneamides of formula (I) which are useful as transketolase inhibitors: wherein R, R, R, R, R, R, R-R, n and ring A are as defined herein. The present invention also provides pharmaceutical compositions comprising the compounds of formula (I). The invention provides methods for inhibiting transketolase activity, reducing cellular ribose-5-phosphate levels, inhibiting nucleic acid synthesis, inhibiting cell proliferation and tumor cell growth in vitro and in vivo, stimulating apoptosis in tumor cells and treating cancer by administering a compound of formula (I) or a pharmaceutical composition thereof. 

Thioalkeneamides as transketolase inhibitors

Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Heterobicyclic pyrazole compounds and methods of use

Growing community of inventors

Kearney, NE, United States of America

Allen A Thomas